[go: up one dir, main page]

PE20050253A1 - Modificaciones estables de maleato de hidrogeno de tegaserod - Google Patents

Modificaciones estables de maleato de hidrogeno de tegaserod

Info

Publication number
PE20050253A1
PE20050253A1 PE2004000706A PE2004000706A PE20050253A1 PE 20050253 A1 PE20050253 A1 PE 20050253A1 PE 2004000706 A PE2004000706 A PE 2004000706A PE 2004000706 A PE2004000706 A PE 2004000706A PE 20050253 A1 PE20050253 A1 PE 20050253A1
Authority
PE
Peru
Prior art keywords
hydrogen maleate
tegaserod
ray
stable modifications
tegaserod hydrogen
Prior art date
Application number
PE2004000706A
Other languages
English (en)
Inventor
Sabine Pfeffer
Christian Vitzling
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34135099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050253(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20050253A1 publication Critical patent/PE20050253A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal Substances (AREA)
  • Glass Compositions (AREA)

Abstract

REFERIDA A UNA MODIFICACION ESENCIALMENTE PURA DEL CRISTAL A DE MALEATO DE H DE TEGASEROD PRESENTANDO DETERMINADOS VALORES EN EL ANALISIS DE CRISTAL DE RAYOS X, UN PATRON DE DIFRACCIONDE POLVOS DE RAYOS X CUYOS VALORES q SON: 5.4 ± 0.3°, 6.4 ± 0.3°, 10.8 ± 0.3°, 16.2 ± 0.3°, ENTRE OTROS; UNA SENAL ENDORTERMICA DE APROX. 190°C EN EL TERMOGRAMA EN CALORIMETRIA DE EXPLORACION DIFERENCIAL. TAMBIEN REFERIDA A UNA PROCESO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA QUE COMPRENDA UN VEHICULO ADEMAS. DICHO MEDICAMENTO ES UTIL PARA EL TRATAMIENTO DE SINDROME DE INTESTINO IRRITABLE, REFLUJO GASTROESOFAGICO, CONSTIPACION CRONICA, DIARREA, ENTRE OTROS
PE2004000706A 2003-07-24 2004-07-22 Modificaciones estables de maleato de hidrogeno de tegaserod PE20050253A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48963803P 2003-07-24 2003-07-24

Publications (1)

Publication Number Publication Date
PE20050253A1 true PE20050253A1 (es) 2005-06-03

Family

ID=34135099

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000706A PE20050253A1 (es) 2003-07-24 2004-07-22 Modificaciones estables de maleato de hidrogeno de tegaserod

Country Status (24)

Country Link
US (1) US20070112056A1 (es)
EP (2) EP1880992A1 (es)
JP (1) JP2006528609A (es)
KR (1) KR20060040710A (es)
CN (1) CN1826318A (es)
AR (1) AR045081A1 (es)
AU (1) AU2004263285A1 (es)
BR (1) BRPI0412830A (es)
CA (1) CA2532351A1 (es)
CO (1) CO5680418A2 (es)
EC (1) ECSP066306A (es)
IL (1) IL172914A0 (es)
IS (1) IS8321A (es)
MA (1) MA27935A1 (es)
MX (1) MXPA06000917A (es)
MY (1) MY137386A (es)
NO (1) NO20060915L (es)
NZ (1) NZ544596A (es)
PE (1) PE20050253A1 (es)
RU (1) RU2349585C2 (es)
SG (1) SG144944A1 (es)
TN (1) TNSN06024A1 (es)
TW (1) TW200510302A (es)
WO (1) WO2005014544A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1723106A2 (en) * 2004-10-19 2006-11-22 Teva Pharmaceutical Industries Ltd. Purification of tegaserod maleate
BRPI0606898A2 (pt) * 2005-01-31 2009-07-21 Novartis Ag uso de agonista de 5-ht4 na preparação de medicamentos e método útil no esvaziamento gástrico retardado
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
BRPI0605901A (pt) * 2005-06-22 2007-12-18 Teva Pharma formas polimórficas de maleato de tegaserode
WO2007119109A2 (en) * 2005-10-06 2007-10-25 Medichem, S.A. Processes for preparing tegaserod maleate and pharmaceutical compositions containing it
GB0524668D0 (en) * 2005-12-02 2006-01-11 Novartis Ag Organic compounds
WO2007120924A1 (en) * 2006-04-17 2007-10-25 Teva Pharmaceutical Industries Ltd. Preparation of tegaserod maleate free of iodide
EP1956002A1 (en) * 2007-02-07 2008-08-13 Chemo Ibérica, S.A. New tegaserod maleate polymorphs and process for their preparation
WO2008142445A1 (en) * 2007-05-17 2008-11-27 Generics [Uk] Limited Process for the preparation of form a of tegaserod

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01242588A (ja) * 1988-03-25 1989-09-27 Chiba Gosei Kenkyusho:Kk ７―シアノメチルチオアセトアミド―７α―メトキシ―３―（１―メチル―１Ｈ―テトラゾール―５―イル）チオメチル―３―セフェム―４―カルボン酸の結晶及びその製造方法
HUT64023A (en) * 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
JPH08291140A (ja) * 1995-04-20 1996-11-05 Teikoku Chem Ind Corp Ltd 易吸収性結晶
ATE316782T1 (de) * 1998-08-21 2006-02-15 Novartis Pharma Gmbh Neue orale formulierungen für 5-ht4 agonisten oder antagonisten
EP1321142A1 (en) * 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
CN1176077C (zh) * 2003-01-07 2004-11-17 江苏省药物研究所 马来酸替加色罗一水结晶
WO2004085393A1 (en) * 2003-03-25 2004-10-07 Hetero Drugs Limited Novel crystalline forms of tegaserod maleate
KR20060111675A (ko) * 2003-12-16 2006-10-27 테바 파마슈티컬 인더스트리즈 리미티드 테가세로드 염기 및 그것의 염의 다형태
US20050272802A1 (en) * 2004-04-22 2005-12-08 Sundaram Venkataraman Process for preparing form I of tegaserod maleate
BRPI0605901A (pt) * 2005-06-22 2007-12-18 Teva Pharma formas polimórficas de maleato de tegaserode

Also Published As

Publication number Publication date
IL172914A0 (en) 2006-06-11
RU2349585C2 (ru) 2009-03-20
RU2006105481A (ru) 2007-09-20
TNSN06024A1 (en) 2007-10-03
NO20060915L (no) 2006-04-24
ECSP066306A (es) 2006-07-28
CA2532351A1 (en) 2005-02-17
KR20060040710A (ko) 2006-05-10
MA27935A1 (fr) 2006-06-01
MXPA06000917A (es) 2006-03-30
SG144944A1 (en) 2008-08-28
EP1651601A1 (en) 2006-05-03
AR045081A1 (es) 2005-10-12
JP2006528609A (ja) 2006-12-21
WO2005014544A1 (en) 2005-02-17
EP1880992A1 (en) 2008-01-23
CN1826318A (zh) 2006-08-30
BRPI0412830A (pt) 2006-09-26
NZ544596A (en) 2009-01-31
US20070112056A1 (en) 2007-05-17
TW200510302A (en) 2005-03-16
IS8321A (is) 2006-02-22
AU2004263285A1 (en) 2005-02-17
MY137386A (en) 2009-01-30
CO5680418A2 (es) 2006-09-29

Similar Documents

Publication Publication Date Title
EP2683383B1 (en) Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2-6-dione in treatment of immune-related and inflammatory diseases
MEP36608A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
MY137535A (en) New pyrrolidinium derivatives
AU2304300A (en) Indole derivatives and their use as mcp-1 receptor antagonists
NO20062713L (no) 2,6 bisheteroaryl-4-aminopyrimidiner som adenosin reseptor antagonister
PE20050253A1 (es) Modificaciones estables de maleato de hidrogeno de tegaserod
HUP0302474A2 (hu) Terápiásan hatásos tropánszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
NO20031370D0 (no) Höy afinitets småmolekyl C5A reseptor modulatorer
TR200001132A2 (tr) İmalat maddeleri
PL370529A1 (en) Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug
BR0015322A (pt) Derivados de indeno-, nafto- e benzociclohepta-dihidrotiazol, sua preparação e seu emprego como medicamentos anoréticos
Dolengevich-Segal et al. An approach to the new psychoactive drugs phenomenon
HUP9700806A2 (hu) Tianeptin-nátriumsó nyújtott felszabadulását biztosító, szájon át beadható mátrix tabletta és eljárás előállítására
RU2012112839A (ru) Новая парентеральная композиция карбамазепина
DE60041655D1 (de) Auslösender rezeptor der an der natürlichen cytotoxizität der menschlichen natürlichen killerzellen (natural killer cells) beteiligt ist und antikörper die diesen rezeptor identifizieren
Swayze et al. Synthesis of 1-(2-aminopropyl) benzimidazoles, structurally related to the TIBO derivative R82150, with activity against human immunodeficiency virus
NO962655D0 (no) Deutrerte virkestoffer i transdermal applikasjon
CL2002001701A1 (es) Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno.
PE20011080A1 (es) Uso de mirtazapina para el tratamiento de trastornos del sueno
AR002727A1 (es) El uso de ridogrel para la fabricacion de un medicamento util para el tratamiento de enfermedades digestivas inflamatorias, una composicionfarmaceutica que comprende ridogrel y un procedimiento para preparar dicha composicion.
Filippi et al. Effects of NCX 4050, a new NO donor, in rabbit and human corpus cavernosum
BR0313224A (pt) Composição farmacêutica contendo composto para terapia da disfunção sexual para ser administrada de modo oral que proporciona rápido inìcio de seus efeitos farmacológicos
CN102317261A (zh) 三重再摄取抑制剂及其应用方法
PE20011121A1 (es) Composicion farmaceutica que comprende un compuesto ciclico con un grupo sulfamato
DE50202865D1 (de) Herstellung reiner stereoisomere von tricyclo-[5.2.1.0(2.6) ]-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration
FD Application declared void or lapsed